Kura Oncology KURA 深 滬
已收盤 08-07 16:00:00 美东时间
9.57
+0.290
+3.13%
華盛通- 最 高9.60
- 今 開9.37
- 成交量 74.93万股
- 最 低 9.339
- 昨 收 9.28
- 總市值 8.50亿
- 52周最高 12.49
- 市盈率 靜 --
- 換手率 0.84%
- 52周最低 6.95
- 委 比 48.34%
- 總股本 8877.44万
- 歷史最高 43.00
- 量 比 0.69
- 振 幅 2.81%
- 歷史最低 2.50
- 每 手 1
- 風險率 1.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology granted inducement stock options to six new employees under its 2023 Inducement Option Plan. The options, totaling 104,500 shares with an exercise price of $9.19 per share, vest over four years. The grant aligns with Nasdaq Listing Rule 5635(c)(4) and is part of the company's commitment to precision medicine in cancer treatment.
08-07 11:30
Kura Oncology Enhances Executive Severance, Change-in-Control Terms
Kura Oncology ( ($KURA) ) has shared an announcement. On July 24 and July 27, 2...
07-30 05:28
美股大行评级 | 潜在涨幅129.15%！HC Wainwright & Co.升Q32 Bio(QTTB)目标价至36美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Q32 Bio"买入"评级，目标价从13美元升至36美元；Chardan Capital：维持ProMIS Neurosciences"买入"评级，目标价从20美元升至33美元
07-29 11:37
Wedbush Reiterates Outperform on Kura Oncology, Maintains $36 Price Target
Wedbush analyst Robert Driscoll reiterates Kura Oncology (NASDAQ:KURA) with a Outperform and maintains $36 price target.
07-28 20:55
Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
Kura Oncology announced updated Phase 1a results from the FIT-001 trial showing encouraging clinical activity of darlifarnib plus cabozantinib in cabozantinib-naïve patients with advanced clear cell renal cell carcinoma (ccRCC). The combination demonstrated a response rate of 33%-50%, median PFS of 13 months, and durable clinical benefit. Safety was manageable, consistent with individual agent profiles. The findings support the potential of darli...
07-27 10:32
Kura Oncology To Feature Updated Phase 1a Results From Ongoing FIT-001 Phase 1a/1b Clinical Trial Evaluating Darlifarnib In Combination With Cabozantinib In Advanced Renal Cell Carcinoma In Oral Presentation At 2026 KCRS
– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients – – Updated data expected to support darlifarnib’s potential to enhance VEGFR-targeted therapy in ccRCC – – Global randomized Phase 1b study c...
07-14 19:21
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology granted inducement stock options to five new employees on July 1, 2026, under its 2023 Inducement Option Plan. The options, totaling 68,750 shares with an exercise price of $10.78 per share, vest over four years, with 25% vesting after one year and the remainder vesting monthly over the next 36 months. The grant aligns with Nasdaq Listing Rule 5635(c)(4) and is subject to the terms of the Company’s option plan and agreements.
07-03 11:30
美股大行评级 | 大摩再上调希捷科技和西部数据目标价；多家大行首予Lincoln买入评级
今日重点评级关注：HC Wainwright & Co.：维持Elicio Therapeutics"买入"评级，目标价从17美元升至23美元；Leerink Partners：维持SAB Biotherapeutics"跑赢大市"评级，目标价从7美元升至12美元
06-16 11:34
Kura Oncology And Kyowa Kirin Announce Long-Term Results From The Phase 1/2 KOMET-007 Single-Arm Trial Evaluating Ziftomenib In Combination With Intensive Chemotherapy
Kura Oncology, Inc. (NASDAQ:KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today announced encouraging long-term results from the Phase 1/2 KOMET-007 single-arm trial (NCT05735184) evaluating ziftomenib in combination with intensive chemotherapy, 7+3, in newly diagnosed NPM1-m or KMT2A-r...
06-11 20:09
